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Abstract: Neurodegenerative disorders are desperately lacking treatment options. It is imperative
that drug repurposing be considered in the fight against neurodegenerative diseases. Fenamates
have been studied for efficacy in treating several neurodegenerative diseases. The purpose of this
review is to comprehensively present the past and current research on fenamates in the context of
neurodegenerative diseases with a special emphasis on tolfenamic acid and Alzheimer’s disease.
Furthermore, this review discusses the major molecular pathways modulated by fenamates.
Keywords: tolfenamic acid; mefenamic acid; flufenamic acid; meclofenamic acid; fenamate; NSAID;
neurodegenerative; Alzheimer’s disease
1. Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed ther-
apeutics, such as ibuprofen and aspirin, that are well-documented for exerting anti-
inflammatory, analgesic, and antipyretic effects [1]. These effects are due to the ability of
NSAIDs to inhibit cyclooxygenases (COX), which prevents the conversion of arachidonic
acid to eicosanoids resulting in a reduction of proinflammatory prostaglandin (PG) syn-
thesis [2,3]. Thus, NSAIDs have been prescribed to treat a variety of illnesses including
migraines, pain, arthritis, fever, and blood clots.
The first NSAID, acetylsalicylic acid or aspirin, was synthesized in 1897 by Felix
Hoffmann [3]. The mechanistic pathway of NSAIDs was not fully understood until the
early 1990s, approximately 90 years after the production of aspirin when COX enzymes
and PGs were characterized [4]. COX enzymes are found in the cardiovascular, neuronal,
renal, immune, gastrointestinal, and reproductive systems in the human body [4]. There are
two well-characterized cyclooxygenase isoenzymes known as COX-1 and COX-2. COX-1,
the constitutive isoform, produces PGs, which are involved in cellular “housekeeping”
and gastrointestinal protection [5]. COX-2 is constitutively expressed in the kidney and
brain and is inducible in cell types such as macrophages and colorectal cancer cells [6].
It can also be increased by cytokines, growth factors, and other inflammatory stimuli [7].
COX-1 inhibition in the gastrointestinal tract causes a reduction in prostaglandin secretion
and its cytoprotective effect in the gastric mucosa, which may lead to the development of
gastrointestinal ulcers, and thus COX-2 inhibitors were originally thought to be safer [8].
All NSAIDs inhibit both COX-1 and COX-2 in vitro, as they are nonselective. Generally,
the ratio between the 50% inhibitory concentration (IC50) values for COX-1 and COX-
2 have been used to determine the selectivity of the therapeutics [6]. However, these
criteria have been described as arbitrary terms to characterize “selective” vs. “nonselective”
inhibitors [6]. Notably, in 2004, Merck and Co announced the voluntary withdrawal of
a popular COX-2 inhibitor, rofecoxib (Vioxx), worldwide after substantial evidence from
the VIGOR study and several other large randomized controlled clinical trials proving
increased risk of cardiovascular events following usage of the drug [5,9].
Cells 2021, 10, 702. https://doi.org/10.3390/cells10030702 https://www.mdpi.com/journal/cells
Cells 2021, 10, 702 2 of 16
Fenamates are a subgroup of NSAIDs, derived from a fenamic acid core structure,
which includes several major clinically prescribed drugs such as mefenamic acid (MFA),
tolfenamic acid (TA), meclofenamic acid (MCFA), and flufenamic acid (FFA) (Figure 1).
Fenamates are carboxylic acids with pKa values of approximately 4 and are >99% ionized
at physiological pH levels [10]. They are eliminated mainly by hydroxylation and glu-
curonidation and excreted in the urine [10]. MFA is the most potent inhibitor of COX-2,
and TA inhibits both COX-1 and COX-2 [11]. All four fenamates have been studied for
various clinical applications outside of pain relief, including cancer, stroke, Alzheimer’s
disease, Huntington’s disease, and epilepsy.
Figure 1. Fenamate chemical structures: (A) fenamic acid parent structure; (B) mefenamic acid structure; (C) tolfenamic
acid structure; (D) meclofenamic acid structure; (E) flufenamic acid structure.
Fenamates have been implicated as therapeutic for many diseases and ailments outside
of pain management. Research has suggested that fenamates may be great candidates for
drug repurposing because of the wide range of therapeutic benefits. This review focuses
on the multiple atypical uses of fenamates and the mechanistic disease pathways that may
be affected.
The following paper summarizes the available data on the clinically relevant fena-
mates, their potential neuro-clinical impact, and their mechanisms of action, with a special
emphasis on TA and neurodegenerative diseases.
2. Fenamate Pharmacokinetics and Pharmacodynamics
Pharmacodynamically, all fenamates exhibit anti-inflammatory, analgesic, and anti-
pyretic activity through COX inhibition in animal models and humans [12].
2.1. Tolfenamic Acid
Tolfenamic acid or TA is available as Clotam Rapid in Europe, where it is commonly
prescribed to treat migraine headaches and in veterinary care. Typically, 200 mg is pre-
scribed as the dosage for migraine treatment. TA has an oral absorption with a mean
lag time of 32 min and a peak plasma concentration of 11.1 mcg/mL with bioavailability
around 60–75% [13]. TA has a high protein-binding distribution of approximately 99.7%
of the administered dose, with peak plasma concentrations being achieved in 1–2 h af-
ter oral administration [13]. The half-life is 8.1–13.5 h if orally administered and 6.1 h if
taken intravenously, and first-pass metabolism accounts for 20% of the administered dose
and it is eliminated relatively fast hepatically. The LD50 is 225 mg/kg in rats following
oral administration [13]. TA was confirmed to cross the blood–brain barrier after intra-
venous administration in guinea pigs [14]. After administration of 100 mg/kg TA, mouse
serum obtained a concentration of 10.85 µg/mL and the concentration in the brain was
1.21 µg/g [14].
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2.2. Mefenamic Acid
Mefenamic acid or MFA is available in the USA as Ponstel and is prescribed to treat
mild to moderate pain, and is rapidly absorbed following oral administration with a
mean absorption of 30.5 mcg/h/mL with a single oral dose of 500 mg [15]. The typical
dose is 500 mg, and the elimination half-life is approximately 2 h, with peak plasma
levels observed at 2–4 h [15]. Typically, greater than 90% is found bound to albumin
and it is expected to be excreted in human breast milk [15]. MFA is metabolized by
cytochrome p450 enzyme CYP2C9 and approximately 52% of mefenamic acid is excreted
into the urine [15]. Fecal elimination accounts for 20% of the dose mainly in the form of
unconjugated 3-carboxymefenamic acid [15]. MFA is a competitive, time-dependent, and
reversible inhibitor for both COX-1 and COX-2, and up to 80% of oral ingestion typically
absorbed [16].
2.3. Meclofenamic Acid
Meclofenamic acid or MCFA was previously prescribed in 100 mg doses to treat mild
to moderate pain and idiopathic dysmenorrhea in the USA. MCFA is rapidly absorbed
with peak plasma concentrations at 0.5 to 2 h [17]. The elimination half-life ranges from
0.8 to 2.1 h [17]. MCFA is >99% bound to plasma proteins [17]. Approximately 30–62%
is excreted in the urine and the remaining percent excreted in the feces [17]. The LD50 is
between 100 and 109 mg/kg following oral or intraperitoneal in rats [17].
2.4. Flufenamic Acid
Flufenamic acid or FFA is typically prescribed in 200 mg doses per 8 h to treat
rheumatic disorders, pain, and inflammation in several countries such as Japan, Switzer-
land, and Taiwan. The LD50 is 249 mg/kg following oral administration to rats [17]. Other
pharmacokinetic information was not readily available for this drug.
2.5. Adverse Drug Reactions
Approximately 40 years after Felix Hoffman synthesized acetylsalicylic acid, the
evidence demonstrated that aspirin could cause gastrointestinal injury due to its acidic
properties [18]. The risk of gastrointestinal injury can also be attributed to the fact that
COX-1 plays an important protective role in the gut by stimulating the synthesis and
secretion of mucus and bicarbonate, which increases mucosal blood flow and promotes
epithelial proliferation [18]. NSAIDs also increase the risk of kidney damage and nephro-
logical complications and may cause hepatotoxicity due to prostaglandin H synthase
(PHGS)-derived prostanoid inhibition [12]. Hepatotoxicity due to either hypersensitivity
or metabolic aberration is another complication of NSAID use; however, it is less common
than renal cardiovascular and gastrointestinal damage [12]. Cardiovascular events are the
most common adverse reaction to NSAIDs, and the mechanism by which certain COX-2
inhibitors contribute to cardiovascular events is likely due to disbalance between thrombo-
genic and anti-aggregatory prostanoids, and as a result, PGI-2 and prostacyclin formation
decreases [19–21].
3. Fenamates and Alzheimer’s Disease (AD)
Epidemiological studies have shown that a very low frequency of Alzheimer’s disease
(AD) is reported in patients who have rheumatoid arthritis or leprosy and are treated
with NSAIDs for a prolonged period [22]. It has even been suggested that NSAID use
decreases the risk of developing AD, improves cognitive deficits, and slows the decline in
patients with AD [23,24]. However, there has been a great amount of controversy over the
efficacy of NSAID use to prevent AD-related cognitive impairment and biomarkers [25]. A
meta-analysis provided evidence that NSAID use may result in a 20% risk reduction for
AD [26]. Alternatively, the INTREPAD 2-year randomized placebo-controlled trial recruited
cognitively healthy individuals who were deemed at risk of developing dementia and
the trial concluded that the use of naproxen did not affect cognition, magnetic resonance
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imaging (MRI), or cerebral spinal fluid (CSF) biomarkers [25]. Fenamate NSAIDs have
been overlooked in the majority of clinical trials and epidemiological studies. This section
summarizes the available recent literature on the efficacy of fenamate NSAID use on
AD-related biomarkers and cognitive deficits.
AD is characterized by the presence of cortical intracellular tau tangles and extracellu-
lar beta-amyloid plaques and is the most common form of dementia affecting over 5 million
Americans and 14 million people worldwide [27]. There are two forms of AD associated
with onset age. Late-onset AD (LOAD) is the most common form with an onset age of ap-
proximately 65 years. LOAD is considered sporadic—however, there have been risk factors
identified with increased incidence such as the APOE ε4 gene, environmental toxicants,
high-fat diet, and lack of exercise [28]. Early-onset AD (EOAD) accounts for approximately
5–6% of all AD cases and is associated with a rare inherited genetic disposition to develop
AD at a young age [29]. The onset age for EOAD is approximately 30–50 years old.
Currently, there are few drugs approved to treat AD symptoms but there are no Federal
Drug Administration (FDA)-approved drugs that are considered disease-modifying. The
commonly prescribed drugs fall into two classes: cholinesterase inhibitors and N-methyl-
D-aspartic acid (NMDA) receptor antagonists [29]. These therapeutics offer temporary
symptomatic relief but are not considered disease-modifying. Cholinesterase inhibitors
prevent the catalytic breakdown of acetylcholine, an important neurochemical for mem-
ory and learning [29]. Donepezil, galantamine, and rivastigmine are three well-known
cholinesterase inhibitors. NMDA receptor antagonists, such as memantine, aid in regulat-
ing glutamate activity and are typically prescribed for moderate to severe cases of AD [29].
While there are few drug options for individuals affected by AD, disease-modifying treat-
ment options for AD patients are critical as the global population increases and the projected
cases of AD are expected to triple by 2050 [30].
Amyloid precursor protein (APP) is a type I transmembrane protein that may have a
role in neurite outgrowth, synaptogenesis, neuronal protein trafficking, transmembrane
signal transduction, cell adhesion, and calcium metabolism [31,32]. APP cleavage by
the β-secretase, BACE-1, and subsequently by γ-secretase generates Aβ, which forms a
neurotoxic oligomer that aggregates into extracellular plaques in AD [29]. Of note, BACE-1
activity is considered the rate-limiting factor in Aβ production from APP [31].
TA has been extensively studied for several potential disease-modifying effects in
AD models. To our knowledge, TA treatment was first reported to decrease AD-related
biomarkers in 2011 when researchers found that both 10 and 50 mg/kg of TA every other
day for five weeks significantly reduced APP protein levels in the cerebral cortices of
female and male C57Bl/6 mice [33]. The proposed mechanism by which TA lowered APP
was via specificity protein 1 (SP1) transcription factor degradation [33,34]. Additionally,
TA treatment lowered Aβ (1–42) levels in the cerebral cortices of treated guinea pigs,
although not significantly. Another study reported that TA-treated hemizygous R1.40
mice administered 5 or 50 mg/kg/day resulted in a reduction of cortical APP protein and
mRNA and reversed cognitive deficits as measured by the Morris water maze (MWM)
and the Y-maze [35]. In the same study, TA lowered SP1 protein levels and soluble and
insoluble Aβ1–40 and Aβ1–42 [35]. In differentiated SH-SY5Y human neuroblastoma cells,
TA treatment lowered SP1 protein levels, reduced APP gene expression, and lowered
lead-induced Aβ40 [36]. Adwan et al. (2014), also reported that TA treatment lowered
BACE-1 gene expression and activity level in the cerebral cortices of APP YAC transgenic
mice. Furthermore, human neuroblastoma cells treated with TA had significantly decreased
protein levels of APP [37].
Currently, the hypothesis associated with TA treatment and its efficacy as an AD treat-
ment revolves around SP1 degradation [34]. SP1 is an upstream zinc-finger transcription
factor that regulates transcription of APP, microtubule-associated protein tau (MAPT),
and cyclin-dependent kinase-5 (CDK5) activator genes and it is elevated in the frontal
cortex of AD patients and the brains of AD transgenic mice [38]. In fact, silencing the
Sp1 gene by small interfering RNA (siRNA) resulted in a 75% decrease in the responsive-
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ness of the human APP promoter and SP1 and Aβ being co-localized in brains of AD
patients [39,40]. The SP1 hypothesis aims to intercept upstream AD pathogenesis to result
in a downstream decrease of key biomarkers: Aβ, tau, CDK5, and BACE-1. Initially, TA
was studied for amyloid pathology effectiveness. However, recently, TA has been proven
to be effective on tau pathogenesis, in vitro and in vivo, which further recapitulates the
SP1 hypothesis [37,41,42].
The amyloid theory of AD has faced controversy in recent years. Although amyloid
appears necessary for cognitive decline, it does not seem to be sufficient, nor does amyloid
accumulation correlate well with the degree of cognitive decline [29,43]. However, there
is sufficient evidence proving that amyloid pathology may be required for tau pathology
progression in AD, including studies that have shown that tau pathology generally does
not progress from the entorhinal cortex into the neocortex in the absence of co-occurring
amyloid pathology [29,44]. The MAPT gene was first isolated and characterized in 1975
and, normally, tau has important roles in microtubule assembly, microtubule stability, and
regulation of axonal transport; however, when tau is hyperphosphorylated, it loses affinity
for microtubules and eventually aggregates, forming intracellular tau tangles [45,46]. The
hyperphosphorylation of tau is mediated by several kinases including CDK5 and glycogen
synthase kinase-3 beta (GSK3β) [47].
In 2015, one study reported that short-term TA treatment resulted in significantly
reduced tau and CDK5 gene and total protein levels and gene expression in APP YAC
mice [38]. Additionally, TA has significantly decreased total tau and phosphotau (ptau),
sites Thr231 and Thr181, protein levels in human tau (hTau) transgenic mice specifically in
the CA3 hippocampal region [42]. Recently, two studies confirmed the efficacy of TA on
significantly reducing ptau (Ser202 and Ser396) in C57Bl/6 mice and increasing expression
of p-AKT (Ser473) and p-GSK3β (Ser9) only 4 to 6 h after administration in Wistar rats [41].
In the same study, TA treatment also reduced ptau (Ser396, Thr231) in vitro, and decreased
p-PP2A (Tyr307), a protein phosphatase that mediates almost 70% of phosphatase activity,
in vitro and in vivo [41].
The cognitive enhancement effects of TA treatment have been well-documented. hTau
transgenic mice administered TA for 34 days had significantly reduced escape latencies
during the MWM test on day 6, and TA-administered mice spent significantly more time in
the correct quadrant during the probe trial [42]. These effects were sustained in mice from
3–4 months of age and in mice 16–18 months of age [42]. In another study, TA treatment
also increased the preferential index percentage during the novel object recognition test
after short-term treatment (25 days), spent longer times in the correct quadrant during
MWM testing, and decreased the amount of error during the passive avoidance test [41].
The overall efficacy that TA exhibits on AD-related biomarkers is still being uncovered;
however, it relies on the presence of tau [37]. In a tau knockout model, mice administered
TA for 34 days traveled significantly less distance and had decreased protein levels of
CDK5 and co-activator p25 than hTau control mice [37]. Both tau knockout mice and hTau
mice had reduced protein expression of COX-2, suggesting that TA treatment alters protein
expression and improves memory retention in the presence of tau and that the mechanism
of tau pathway alterations is independent of its COX inhibitory properties [37].
Inflammation has recently become a major area of focus for neurodegenerative re-
search and Alzheimer’s disease. Many neurodegenerative diseases are accompanied by
neuroinflammation as an overarching symptom or possible contributor to the disease. The
NLR family pyrin domain-containing 3 (NLRP3) inflammasome is commonly associated
with inflammatory diseases, including AD, as Aβ is a known activator [2]. The NLRP3
inflammasome is a critical component of the innate immune system and is composed of
NLRP3, associated speck-like protein (ASC), and pro-caspase-1 [48,49]. Daniels et al. (2016)
reported that both FFA and MFA inhibited this pathway, in vitro and in vivo, via inhibition
of voltage-gated anion channels (VRAC) [2]. Furthermore, MFA treatment prevented
Aβ1–42-induced memory deficits in rats and memory deficits in 3X TgAD transgenic mice
as measured by the novel object recognition (NOR) test [2]. MFA was also effective in
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decreasing the production of nitric oxide and reducing cytochrome c release from mito-
chondria induced by Aβ1–42 in vitro, and attenuated learning and memory impairment
in an Aβ1–42-infused AD rat model [1]. MFA treatment also ameliorated AD-related neu-
roinflammation in 3X TgAD transgenic mice by reducing microglial activation to that of
wild-type mice [2]. In agreement with this study, Feng et al. (2020) reported that MFA
treatment reduced activated and phagocytic microglia in the dentine gyrus area of the hip-
pocampus in wild-type mice [50]. Another important inflammatory target is nuclear factor
kappa B (NF-κB), which is a sequence-specific transcription factor. NF-κB regulates a broad
range of genes involved in inflammation, apoptosis, and tumorigenesis. In the presence
of inflammatory stimuli, TA downregulates NF-κB signaling [51]. In another study, FFA
inhibited the NF-κB signaling pathway at low concentrations [52]. Overall, these results
demonstrate that fenamates have clinical significance as AD- and inflammation-targeting
drug candidates.
In AD patients, neurotoxic levels of D-serine, the co-agonist for NMDA receptors,
have been reported in the hippocampus and is involved in the pathogenesis of AD and
neuroinflammation [53]. According to Armagan et al. (2012), MFA treatment protected
against the elevation of lipid peroxidation, protein oxidation, and inflammatory targets in
the Sprague-Dawley rat brains and may be an effective therapeutic for D-serine-induced
neuroinflammation [53].
4. Fenamates and Cognitive Impairment
As healthcare has improved, life expectancy has extended, leading to substantial
increases in the number of individuals over the age of 65 years old who are at risk of
developing cognitive impairment and dementia [54]. Mild cognitive impairment (MCI),
a term used for over four decades, describes individuals with a noticeable decline in
cognitive abilities that does not interfere with their daily functioning [55]. There are
many different etiologies of MCI, including vascular, neurodegenerative, psychiatric,
and medical [56–58]. Pharmacological interventions are limited and systematic reviews
using randomized controlled trials have not investigated a protective effect of dementia
medications or NSAIDs [54]. The following section focuses on studies where fenamates
have been used to treat non-AD-related cognitive impairment from different etiologies.
4.1. Fenamates and Tauopathies
In AD, the characteristic hallmarks are Aβ plaques and neurofibrillary tau tangles
(NFTs), and the earliest symptom of AD is cognitive impairment, as mentioned above.
Many studies have suggested that the progression of mild cognitive impairment found
in AD is most closely associated with NFT formation than Aβ plaque load [43]. Tau
aggregation is not unique to AD; in fact, tau aggregation accounts for more than 20 neu-
rological disorders known as tauopathies, which include AD, frontotemporal dementia
with parkinsonism-17 (FTD-17), progressive supranuclear palsy (PSP), corticobasal degen-
eration, chronic traumatic encephalopathy, and Parkinson’s disease (PD) [59]. Moreover,
therapeutics that are useful for one tauopathy may be therapeutic in others to combat
cognitive decline. In fact, TA has been designated by the FDA and European Medicines
Agency (EMA) as an orphan drug for the treatment of PSP, with a clinical trial currently
under final approval to evaluate TA in individuals with PSP (NCT04253132).
4.2. Fenamates and Chronic Alcohol Exposure
Alcoholism is a chronic disorder, accounting for 5.3% of all deaths worldwide, that
is known to be highly correlated with multiple neuropsychiatric diseases and cognitive
impairment [30,60]. Several studies have shown that over-consumption of alcohol is a risk
factor for dementia via many proposed pathways. Chronic alcohol use and withdrawal
may stimulate Toll-like receptors (TLRs) 2 and 4, which could directly lead to microglial
activation, neuroinflammation, and neuronal death [30]. Studies have also demonstrated
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that alcoholic individuals have increased Iba-1 expression, which is a marker of microglial
expression [61].
Rajesh et al. (2017) observed that chronic alcohol exposure produced cognitive im-
pairment in zebrafish, evidenced by the inability to retain the memory of a learned task,
whereas zebrafish exposed to alcohol and MFA significantly retained memory of the learned
task [62]. Furthermore, MFA exposure decreased acetylcholine esterase (AChE) activity in
the brain of alcohol-exposed zebrafish [62]. The proposed mechanism for the protective
effect was a generation of MFA free radicals during interaction with peroxidase, which was
originally reported by Muraoka and Miura (2009) [22].
4.3. Fenamates and Ischemic Injury
Cerebral ischemia due to cerebral vessel blockage is a leading cause of death world-
wide and neurons are uniquely vulnerable to ischemic injury [63,64]. According to the
American Heart Association, stroke is the fifth leading cause of death in the United
States [65]. Stroke is typically classified into two categories: ischemic or hemorrhagic [66].
Glutamate-induced excitotoxicity, reperfusion injury due to reactive oxygen species (ROS),
neuroinflammation mediated by excessive microglia activation, and impaired axonal re-
generation have all been proposed as potential underlying mechanisms of ischemic brain
injury [67].
Studies have shown that many fenamates have neuroprotective effects against
excitotoxicity-induced cell death [64,68]. MFA and MCFA have been proven to be neuro-
protective against glutamate-evoked excitotoxicity in cultured embryonic rat hippocampal
neurons, and intracerebroventricular (ICV) administration of MFA for 24 h reduced brain
damage in rodents [68]. In another study, treatment with MFA reduced cerebral edema,
infarct volume, total ischemic brain damage, and edema, which provided evidence that
fenamate NSAIDs may be neuroprotective against ischemic stroke [69].
5. Fenamates and Huntington’s Disease
Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disorder
caused by the abnormal expansion of the cytosine–adenine–guanine (CAG) repeat in
the IT15 gene located on chromosome 4 [70]. This results in the production of mutant
huntingtin (mHtt) protein with a long polyglutamine stretch in the N-terminus region of
the Huntingtin protein (Htt) [70,71]. Individuals with greater than 39 CAG repeats develop
HD, while those with 36–39 have reduced penetrance [71].
The mean prevalence of HD is estimated at 5.5 cases per 100,000 in the world [72].
Common symptoms are motor dysfunction, psychiatric disturbance, and cognitive deficits
including chorea and loss of coordination [71,73]. mHtt causes selective neuronal loss in
the striatum (caudate nucleus and putamen) with specific loss of efferent medium spiny
neurons (MSNs) and dysfunction in the brain through multiple mechanisms [71,73]. The
presence of mutant huntingtin aggregates found initially in the nucleus and later in the
cytoplasm and neuronal processes, are considered the hallmark of HD [73].
The most common mouse model of HD is the R6 transgenic model that expresses a
truncated form of the human Htt and has been used to examine therapeutic strategies [70].
The human htt gene is among many that are regulated by Sp1, which suggests that TA may
be an effective treatment to attenuate motor and cognitive deficits for HD patients [74]. In
fact, R6/1 mice treated with TA demonstrated improved motor performance in the rotarod
test and attenuated cognitive decline, as observed during the novel object recognition (NOR)
and passive avoidance tests [70]. Furthermore, TA treatment significantly decreased protein
expression of mHtt and SP1 in vivo, and alleviated oxidative stress in PC12 cells [70]. These
results suggest that TA treatment may facilitate the clearance of mutant Htt aggregates by
SP1 inhibition and activation of the autophagy pathway [70].
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6. Fenamates and Epilepsy
Epilepsy is a neurological disorder characterized by recurrent unprovoked seizures
and is the fourth most common neurological disorder affecting approximately 50–65 mil-
lion people worldwide [75,76]. Cognitive impairment, mood, and behavior disorders are
common comorbidities of epilepsy [77]. Epileptic dementia is a term that was coined in
the 19th century based on the idea that epilepsy causes progressive cognitive decline [77].
Currently, epilepsy therapeutics target ion channels or neurotransmitter systems; how-
ever, these treatments only provide relief for 60% of patients [76]. The following section
reviews how fenamates are known to modulate several ion channels that are implicated in
epileptogenesis.
Physiologically, epilepsy is linked to neuronal hyperexcitability [78]. The regulation of
excitability is partially controlled by subthreshold, voltage-gated K+ currents (M-currents)
that are generated by M-type K+ channels [78]. The low-threshold gating and slow activa-
tion and deactivation of the M-current provide relief from repetitive firing and neuronal
excitability [78,79]. According to Peretz et al. (2005), MCFA is a potent and specific opener
of KCNQ2/Q3 channels, enhanced M-currents, and reduced evoked action potentials [78].
Voltage-gated sodium channels (VGSC) have also been linked to neuronal disorders
such as epilepsy, autism, muscle disease, and pain [80]. The VGSC subtypes Nav1.7 and
Nav1.8 have been implicated as targets for pain management [80]. MFA, FFA, and TA
inhibited peak sodium currents and significantly affected the inactivation processes of
hNav1.7 and hNav1.8 with I-V curves left-shifted to the hyperpolarized direction. These
findings may contribute to the well-known analgesic effects of these fenamates [80]. In
another study, FFA inhibited VGSC currents in hippocampal pyramidal neurons by slowing
down the inactivation process of the sodium current and shifting the inactivation curve
toward more hyperpolarized potentials [81].
7. Overview of Alternative Drugs
In this review, we have discussed three key neurodegenerative pathways modulated
by fenamates (Figures 2 and 3). It is also imperative to acknowledge the originality of
each major mechanism and other drugs that may provide similar effects. The following
section overviews the currently approved or potentially therapeutic drugs that use similar
molecular mechanisms as stated above.
In the past, NSAIDs were extensively studied for their possible role as cancer ther-
apeutics. Chronic inflammation has been linked widely to carcinogenesis, and epidemi-
ological studies have indicated the chemoprotective and chemopreventive properties of
NSAIDs [82]. Fenamate NSAIDs are known to modulate several pathways and exhibit
anti-tumor activities in models for several cancers [83–86]. In fact, The SP1 hypothesis
for AD intervention originated from cancer research as SP1 is upregulated in various
types of cancer [87]. Although TA is unique among NSAIDs for its’ ability to target
SP1, TA is not the only known therapeutic able to modulate SP1 binding and activity.
Mithramycin (MTM) is an antineoplastic antibiotic that has been proven to bind to GC-rich
DNA sequences and thus interferes with transcription factors that bind to GC-rich DNA
regions, such as SP1 [87–89]. It has also been suggested that MTM can selectively inhibit
SP1 but the mechanism is not well understood [87]. MTM treatment reduced cerebral
Aβ levels and plaque burden, inhibited APP processing, alleviated tau hyperphosphory-
lation, and inhibited phosphorylated CDK5 and GSK3β pathways in APPswe/PS1dE9
mice [90]. MTM treatment also upregulated synaptic plasticity gene expression in an AD
model in vitro, and prolonged survival and improved motor performance in an HD mouse
model [89,91]. Collectively, these reports support the SP1 hypothesis for neurodegenerative
disease intervention.
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Figure 2. Proposed transcriptional mechanism of action for tolfenamic acid. Tolfenamic acid inhibits specificity protein 1
(SP1)-DNA binding, which leads to decreased expression of amyloid precursor protein (APP), mutant huntingtin protein
(mHtt), β-secretase-1 (BACE-1), and cyclin-dependent kinase-5 (CDK5). The bottom half of the illustration shows the impact
of tolfenamic acid on tau tangles via SP1 inhibition.
Figure 3. Mechanistic overview of fenamate neuropharmacology. This figure illustrates several
diseases that can be targeted using fenamates and their three major pathways of interest. Tolfenamic
acid (TA), mefenamic acid (MFA), meclofenamic acid (MCFA), flufenamic acid (FFA), NLR family
pyrin domain-containing 3 (NLRP3), specificity protein 1 (SP1).
Furthermore, the role of COX inhibition in neurodegenerative and neuroinflammatory
treatment or prevention is pertinent to mention. COX-2 is expressed under basal conditions
in neuronal regions that overlap with AD pathogenesis [92]. It has even been suggested that
the overexpression of neuronal COX-2 activity may disrupt normal neuronal function [92].
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Due to the evidence linking COX-2 dysregulation to neurodegenerative diseases, NSAIDs
have been implicated for their potential therapeutic effects in neurodegenerative disease
states, particularly AD. In APP-PS1 mice, administration with ibuprofen during early
adulthood prevented memory deficits [92]. However, the correlation of COX inhibition and
the decreased occurrence or progression of neurodegenerative diseases has been debated
because, although epidemiological data have shown that populations with long histories
of NSAID use were at lower risk of AD, clinical studies have failed to achieve significant
effects in the treatment of AD [93]. These findings may suggest the idea that NSAIDs may
be useful in neurodegeneration prevention but are less useful for treatment; however, there
has been no conclusive data proving their efficacy in prevention in humans.
Alzheimer’s disease is the only top-10 cause of death without a disease-modifying
treatment approved by the FDA. Several recent anti-amyloid therapies have failed in
clinical trials, which has prompted researchers to explore alternative pathways to target [94].
Targeting neuroinflammation is a recent approach that has gained more attention due to
the high failure rate of previous drug candidates [94]. The NLRP3 inflammasome is a well-
known driver of tau pathology and there are several proven direct and indirect inhibitors
of the NLRP3 inflammasome that have been identified [48,95,96]. However, inhibition of
VRAC by MFA is a novel approach to NLRP3 inhibition, and researchers have suggested
that it is important to consider indirect therapeutic methods as targeting the inflammasome
itself may result in peripheral complications [97].
Anti-seizure drugs (ASDs) are the predominant form of treatment for symptomatic
relief for patients living with epilepsy [98]. ASDs interact with a variety of cellular targets
including voltage-gated ion channels, GABAA receptors, GABA transporter 1 (GAT),
synaptic vesicle proteins, ionotropic glutamate receptors, and several other targets of
interest [98]. Currently, there are about 30 ASDs on the market [98]. While targeting
VGSCs is not a novel mechanism, to our knowledge, there are no current commonly
used drugs that target KCNQ2/Q3 channels [99]. Retigabine was discovered in the 1980s
as a potent opener of channels formed by KCNQ2 and KCNQ3 subunits and was used
to treat neonatal epileptic encephalopathy and, unfortunately, it was discontinued in
2017 due to pigmentary changes induced in skin, mucosae, and eyes [79,100]. For acute
ischemic stroke, glutamate-induced excitotoxicity is a well-known contributor to ischemic
neuronal death and has been targeted indirectly by NMDA receptor antagonists [101].
Thus far, there are no FDA-approved drugs for cerebral ischemia that target glutamate
excitotoxicity, to our knowledge, as several have failed in randomized controlled clinical
trials in humans [101]. There have been recent novel advances to combat glutamate-
excitotoxicity, such as introducing glutamate scavengers or “grabbers”, which further
reiterates the idea that glutamate excitotoxicity remains an important target for cerebral
ischemia [102].
8. Discussion and Conclusions
Altogether, we have presented mounting evidence of several non-canonical disease
pathways, from Alzheimer’s disease to epilepsy, that are modulated by various fenamates
(Figures 2 and 3), and there are several significant conclusions to be mentioned in terms
of this review. First, it is important to consider fenamates in neuropathological drug
development as modulating several pathways may provide greater protective effects
than molecules that have single targets, which may allow them to be efficacious at lower
doses [2]. The main benefit may be in lowering inflammation as well as other disease-
specific targets. Fenamates seem to act directly on their targets such as enzymes and ion
channels, as well as indirectly by modulating transcription factors and thus impacting
disease-specific gene expression. Interestingly, the ability of certain fenamates to activate
proteasome-dependent degradation of SP1, and inhibit NLRP3 and certain ion channels
is unique among NSAIDs, which may be indicative of a chemical class effect instead of a
therapeutic class effect (NSAID) [2,34,103]. Drug repurposing offers many benefits as it
may expedite the drug discovery process by shortening the high-throughput screening
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and clinical trial phases and provide proven safe alternatives to existing treatments. This
is particularly important as CNS drugs have high failure rates and tend to have poorly
understood pathways, and often patients have several co-morbidities. Furthermore, it
is important to consider the adverse reactions that have been well documented due to
long-term NSAID use and how the length of therapy and the therapeutic dose required may
determine the safety of these small molecules for age-related disorders. In fact, fenamates
could serve as a scaffold in future therapeutic drug design for neurodegenerative diseases.
Finally, these data suggest the effect that fenamates have is polyvalent and substantiates
the hypothesis that some therapeutic effects are independent of the COX pathway. In the
future, an exploratory pathway analysis and a comprehensive safety profile for each drug
could provide insight into drug mechanisms of action and possible adverse effects specific
to fenamates.
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PHGS Prostaglandin H synthase
AD Alzheimer’s disease
MRI Magnetic resonance imaging
CSF Cerebral spinal fluid
LOAD Late-onset Alzheimer’s disease
EOAD Early-onset Alzheimer’s disease
FDA Federal Drug Administration
NMDA N-Methyl-D-aspartic acid
APP Amyloid precursor protein
BACE-1 β-Secretase-1
SP1 Specificity protein 1
MWM Morris water maze
MAPT Microtubule-associated protein tau
CDK5 Cyclin-dependent kinase-5
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GSK3β Glycogen synthase kinase-3 beta
ptau Phosphotau
hTau Human tau
NLRP3 NLR family pyrin domain-containing 3
NF-κB Nuclear factor kappa B
MCI Mild cognitive impairment
NFT Neurofibrillary tau tangles
FTD-17 Frontotemporal dementia with parkinsonism-17
PSP Progressive supranuclear palsy
PD Parkinson’s disease
EMA European Medicines Agency
TLRs Toll-like receptors
AChE Acetylcholine esterase






MSNs Medium spiny neurons
ASC Associated speck-like protein
VRAC Voltage-gated anion channels
NOR Novel object recognition
VGSC Voltage-gated sodium channels
MTM Mithramycin
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GAT GABA transporter 1
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